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Introduction
Over the last two decades, the health benefits associated 
with increased physical activity have been established.1 
However, with increased participation in physical activity 
comes a subsequent increase in sports and exercise related 
injury. It is estimated that there are over 4.2 million visits to 
the emergency rooms for sport and exercise related acute 
injury in the United States alone, and at least that number 
of visits due to chronic sport and exercise related injury.2,3 
This article will focus on the use of pharmacological agents 
in the acute management of these injuries.
Use of analgesics and non-steroidal  
anti-inflammatory drugs (NSAIDs) in 
sporting competition
It is widely believed that use or abuse of analgesic 
medications and NSAIDs is widespread in sports medicine. 
However, the use of these agents on the African continent 
was previously unknown. In 1996, at the finals of the 
African Nations Cup Football Tournament, we undertook a 
study to investigate this issue. As part of the FIFA testing 
procedure, the team physicians of the 15 teams were asked 
to complete a questionnaire prior to each match. The team 
physicians listed the prescribed medication or supplement 
ingested, injected or taken per rectum for each of the 16 
squad members in the 72 hr period prior to the match.
In total, 32 matches involving 544 player/match exposures 
occurred during the tournament. The composition of all 
agents used by players during the tournament is shown in 
Figure 1. 
Thirty-one per cent of the players had injected NSAID agents 
in the period prior to the match. Of the NSAIDs diclofenac 
was the most common (19%) followed by ibuprofen (5%), 
indomethacin (3%), piroxicam (3%) and acetylsalysilate 
(1%). In four teams, diclofenac and paracetamol were 
prescribed for the entire squad, twice daily, for the three 
day recovery period between matches. For one team, 
each player was administered an intramuscular diclofenac 
injection prior to running onto the field. In seven cases, 
more than one NSAID was prescribed for a player.
These results indicate that whilst prescribing habits vary 
greatly prior to competition, NSAID abuse is very common 
during International level football competition on the African 
continent.  Whilst it might be argued that prescribing patterns 
of these agents might have changed since this study, more 
recent research suggests that NSAIDs use is excessive at 
both FIFA World Cup and Olympic level athletes.4–7 Indeed, 
our results are higher than the reported frequency (of 
ingestion prior to the match) of 20% reported for the FIFA 
2002 and 2006 World Cup competitions.5 It is probable that 
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rates of use of these agents are even higher in recreational 
athletes, especially as some of these agents are available 
for over- the- counter purchase. It is difficult to believe that 
these alarmingly high frequencies of use of these agents 
are for therapeutic reasons and therefore, both athletes 
and medical staff must believe that use of these agents 
might extend some prophylactic benefit to the competing 
athlete. Furthermore, long-term use of these agents is also 
a concern. As these medications are not without significant 
side effects, improved dissemination of knowledge 
regarding the use of the agents as well as guidelines for 
their judicious use in sports medicine should be directed 
at team physicians, general practitioners prescribing 
for recreational athletes and athletes themselves. The 
remainder of this article will review the agents that are used 
for pain management in acute sports injury and suggest a 
rational approach to the use of these agents.  
Pain
Pain is an extremely complex phenomenon. It is defined as 
an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage. Furthermore, pain 
is an individual, multifactorial experience influenced by 
culture, previous pain events, mood and ability to cope. 
Acute pain is defined as “pain of recent onset and probable 
limited duration. It usually has an identifiable temporal and 
causal relationship to injury”.8 Chronic pain “commonly 
persists beyond the accepted time of healing of an injury 
and frequently there may or may not be a clearly identifiable 
cause”.8 More recently, we recognise that acute and chronic 
pain may represent a continuum rather than distinct entities. 
Through tissue injury, phospholipids are released from the 
cell membrane and are converted into arachidonic acid by 
the enzyme phospholipase A2. Arachidonic acid in turn is a 
substrate for the enzyme cyclo-oxygenase (COX) resulting in 
the production of various prostaglandins (PGs). This pathway 
and the substances that are produced are responsible for 
the pain and inflammation seen in sports injury. With respect 
to the COX enzyme, two isoforms have been established 
with different functions. These are COX-1 (constitutively 
present) and COX-2 (induced) (Table I). The older NSAIDs 
inhibit both isoforms of the COX enzymes, whereas COX-2 
specific inhibitors inhibit only the COX-2 isoform (COXIBs), 
with the possibility that selective inhibition of particularly the 
COX-2 isoform could reduce the side effects of NSAIDs but 
still maintain the efficacy of these agents.
As clinicians, we are taught to actively treat and minimise 
the patient’s pain and facilitate return to pre-injury level of 
functioning as quickly as possible, without compromising 
tissue healing. Indeed, many athletically inclined patients 
place significant pressure on their treating physician to 
get them “back up and running” as soon as possible. In 
this endeavour, we use pharmacological agents to treat 
the patient’s pain so that detraining may be minimised 
and rehabilitation can be initiated. These agents might 
include analgesics, topical analgesics, non-steroidal anti-
inflammatory agents, topical anti-inflammatory agents 
and corticosteroids. These agents will be discussed in the 
setting of the different forms of injury and biological tissue 
that is injured. 
Agents used to treat pain
Analgesics
Analgesics are commonly used in the first line management 
of acute sports injury to reduce pain. Further use of the 
analgesics will depend on the intensity and duration of 
pain. Agents in this group include acetylsalicylic acid, 
paracetamol, codeine and tramadol, used either as single 
agents or in combination. 
Acetylsalicylic acid
Acetylsalicylic acid at low doses (up to 300 mg) has both an 
analgesic and antipyretic effect but has an anti-inflammatory 
effect at higher doses. However, at the higher doses, there 
is increased incidence of gastrointestinal side effects. As 
this agent inhibits platelet aggregation and may increase 
bleeding, it does not have a role in the management of 
acute sports injuries.
Paracetamol
Paracetamol has both analgesic and antipyretic effects, 
but does not inhibit the inflammatory response or clotting 
process. It is thus safe for use in acute sports injuries at up 
to 3–4 g/day. The incidence of adverse effects is comparable 
to placebo.9
Table I: Differences between the isoforms of the cyclo-oxygenase enzymes (COX-1 and COX-2)
COX-1 isoform COX-2 isoform
Constitutive Inducible
Mainly physiological effects Release of inflammatory mediators
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Codeine
Codeine is a more potent analgesic from the narcotic group. 
It is usually used in combination with either acetylsalicylic 
acid or paracetamol.10  Its use is reserved for more severe 
pain.
Tramadol
Tramadol is also an effective analgesic from the narcotic 
group. It is also an effective agent in neuropathic pain.11 
However, a recent study has suggested that tramadol has 
lower efficacy and a greater incidence of adverse events 
compared to a COXIB in the management of chronic lower 
back pain.12  Its use in sports medicine is reserved for 
more severe injury, when additional analgesia is required. 
Ongoing need for use of this agent requires reassessment 
of the injury. 
Topical analgesics
The majority of these agents are skin counterirritants and 
contain a combination of substances including methyl 
salicylate, eucalyptus, menthol, capsicum and camphor. 
The active ingredients cause erythema and blood vessel 
dilatation and stimulate the pain and temperature receptors. 
These agents can be used in addition to a warm-up and can 
be of some benefit for minor sprains and strains.13  However, 
they should not be used on broken skin as they can cause 
further irritation, blistering and contact dermatitis. 
NSAIDs
Perhaps the most common agents used in the practice 
of sports medicine today, are the non-steroidal anti-
inflammatory agents. Indeed, for many clinicians these 
agents are the first line of use to decrease pain, swelling and 
the inflammatory response when treating a soft tissue injury. 
One of the main functions of NSAIDs is to reduce the 
production of the substances that cause the inflammatory 
response, and therefore decrease pain, swelling, and loss 
of function following an acute sports injury. However, there 
have always been significant side effects associated with 
the use of NSAIDs, in particular upper gastro-intestinal side 
effects and renal side effects.14 NSAIDs can possibly be 
linked to water retention and hyponatraemia in marathoners, 
but further research on this area of sports medicine is 
warranted.  
Traditional NSAIDs carry the potential for greater adverse 
gastrointestinal (GIT) side effects and their effects on 
healing of tissues remain relatively unknown. However, they 
are not associated with cardiovascular side effects and are 
effective analgesic agents.
Topical NSAIDs
A number of NSAIDs  are available in different formulations 
including creams, ointments, sprays, gels  and patches. 
Agents delivered in these forms include amongst others, 
diclofenac, flubiprofen, ketoprofen and indomethacin. A 
recent systematic review of randomised controlled trials 
concluded that topical NSAIDs are effective in relieving the 
pain associated with soft tissue injuries without causing 
serious adverse effects.15–19 However, NSAID patches are 
not effective in prophylactic use to prevent delayed onset 
muscle soreness (DOMS) in trained athletes.20 
The Cyclo-Oxygenase-2 Inhibitors (COXIBs)
These newer agents were developed to reduce the adverse 
GIT effects of the traditional NSAIDs. Most studies on 
the efficacy of these drugs show that they are effective in 
decreasing pain, swelling and loss of function.21 However, 
the majority of these studies have been conducted in the 
osteoarthritis or rheumatoid arthritis models.21 There are few 
studies on acute sports injuries. However, in some studies 
it has been demonstrated that the COXIBs are as effective 
as the older non-selective NSAIDs in the management of 
ankle sprains and shoulder injuries. Studies show these 
agents generally are effective at decreasing pain and allow a 
quicker return to activity and rehabilitation.12,22–27. However, 
effects of these agents on joint stability and on joint injuries 
other than the ankle and shoulder are unknown. 
In general, the COXIBs are associated with fewer 
gastrointestinal and other side effects compared to the 
non-selective NSAIDs, and there appears to be a sparing 
effect on the kidneys, provided patients are not sodium 
depleted.15  These are advantages over the “older” drugs. 
There has however been some recent concern that 
the COXIBs may be associated with increased risk of 
thrombosis (by inhibiting prostacyclin), and an increased 
blood pressure following administration. However, the 
higher cardiovascular risk of the COXIBs (leading to the 
withdrawal of rofecoxib) compared to the non-selective 
NSAIDs have been seen in relation to some COXIBs but 
not others.21  The Food and Drug Administration,  however, 
commented that the short-term use of NSAIDs and COXIBs 
does not appear to increase cardiovascular risk.  There may 
also be drug interactions, such as with warfarin (rofecoxib), 
cytochrome p-450 inhibitors (celecoxib), and sulphur drugs 
(rofecoxib). These have to be taken into consideration when 
these drugs are prescribed. 
The effects of the (non-selective) NSAIDs and COXIBs on 
the  healing process of various musculoskeletal tissues 
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1.  Bone injury
Whilst the efficacy of the NSAIDs in attenuation of 
the formation of myositis ossificans and ectopic bone 
formation has been shown, the effects of these agents on 
the healing process and on loosening of prostheses require 
further studies.28  NSAIDs have been widely used in the 
management of fracture pain, and their inhibitory effects on 
the bone healing process have raised concerns.28–30 Studies 
evaluating fracture healing in mice treated with NSAIDs or in 
mice lacking the COX-2 gene demonstrate that deficiency of 
COX-2 impairs bone healing.31–33  Limited clinical data also 
support the notion that COX-2 agents delay bone healing.34 
However, this finding has not been replicated in all studies.34 
It is apparent that both the older NSAIDs and newer COXIBs 
negatively affect bone healing to some extent.34,35
2.  Skeletal muscle injury
Using different skeletal muscle injury models in animal 
studies, the COXIBs have shown that they impair healing 
and regeneration, with reduced myofibroblast proliferation 
and in some instances increased fibrosis.36–38  There have 
been limited studies on the effect of the non-selective 
NSAIDs and COXIBs on healing in human athletes. One 
study, investigating the effects of diclofenac patches 
following blunt trauma showed that the intervention was 
safe and effective in reducing pain.17  However, most 
of the available studies have examined the effects of 
these agents on delayed onset muscle soreness (DOMS) 
following eccentric loading exercise. The majority of these 
studies have failed to show any benefit of the administration 
of the anti-inflammatory medication with respect to 
induced muscle pain.20,39–43 Indeed, preliminary work in 
our laboratory has indicated that early administration of 
meloxicam prior to induced eccentric load damage results 
in higher concentrations of creatine kinase compared to 
administration of the agent 48 hours after muscle damage 
is induced. These findings suggest that early treatment with 
meloxicam might increase the extent of muscle damage 
induced by eccentric load exercise.43 
3.  Tendon injury
Animal studies have demonstrated that ligaments from 
celecoxib treated rats could resist less force and were less 
stiff compared to ligaments from control animals.44,45 To 
date there are no studies on humans.
4.  Ligament injury
The effects of the COXIBs have been investigated in animal 
trials using an Achilles tendon, rotator cuff, and patellar 
tendon injury and repair model. Whilst improved tendon 
repair was reported in one study,46 other studies reported 
adverse effects of both COXIBs and non-selective NSAIDs 
on tendon healing.5,6,47   
A review of the above studies certainly suggests that the 
anti-inflammatory agents and indeed both the non-selective 
NSAIDs and the COXIBs have a significant negative effect 
on musculoskeletal tissue healing and this finding remains 
a subject of much debate.40,48–50 This is particularly evident 
with respect to animal study models. Whilst animal studies 
are important precursors in initial evaluation of drug safety 
and efficacy, care should be taken in extrapolating the 
results in many of these laboratory based studies to the 
clinical setting. Further clinical trials with respect to use of 
these agents in the athletic population are urgently needed. 
In particular, the timing of administration of the agent and 
relative dosing (in comparison to animal models) requires 
further study.
Clinical recommendations for use of analgesics 
and anti-inflammatories in sports medicine: Current 
practice in Sports Medicine Practice at the Sports 
Science Institute of South Africa 
• As is evident from the above discussion, the inflammatory 
process seems to be an important part of the healing 
process in the musculoskeletal tissue of humans. 
We therefore use only analgesics in the first 48 hours 
following injury to allow the first part of the physiological 
healing process to occur. Examples of agents that are 
used for pain management in this phase are paracetamol 
or paracetamol plus codeine. 
• Rest, ice, compression and elevation are important 
elements of the patient management in the first 48 hours 
following injury. 
• After 48 hours post-injury, if repeat assessment of the 
injury reveals clinical signs and symptoms of excessive 
inflammation (swelling and pain), we use an NSAID or 
COXIB for up to a limited period (five days) as these 
agents have been shown to reduce pain and promote 
function following injury. 
• If the athlete has a history of gastro-intestinal side effects 
or other side effect following non-selective NSAID use, 
paracetamol should be continued or a COXIB or COXIB 
plus proton pump inhibitor should be considered.  
• Physiotherapy, including therapeutic ultrasound, followed 
by rehabilitation form an essential part of treatment from 
24 hours after injury. 
• Generally, if the use of an NSAID, COXIB or analgesic 
is required for longer than a five day period, the patient 
should be reassessed and the diagnosis revisited.   
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to prevent muscle soreness after exercise or to prevent 
pain during sport.
• There is evidence of efficacy of use of the NSAIDs in the 
following injuries: ligament sprains of the ankle, knee 
and shoulder joints; conditions where the pathological 
disorder is tissue entrapment or impingement of nerves 
and other structures due to soft tissue swelling, for 
example in the following conditions: carpal tunnel 
syndrome, Morton’s neuroma, intervertebral disc 
prolapse, thoracic outlet syndrome, bursitis in rotator 
cuff disease, trochanteric bursitis and the iliotibial band 
friction syndrome.  
• There is no role for NSAIDs in the management of the 
chronic degenerative tendon conditions including 
Achilles tendinosis, as the pathology has been shown 
not to be inflammatory in origin.  Furthermore, there is 
no evidence to support the use of NSAIDs for long-term 
pain from sports injury without impingement.
• Many athletes with sports injury do not take sufficient 
time off their training to allow for complete tissue healing. 
They might in fact ingest these agents to facilitate early 
return to sport which can put them at risk of further 
injury. Adequate time for recovery, physiotherapy and 
rehabilitation should be allowed before returning to 
sport.  
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